Could a prostate drug help fight bladder cancer?

NCT ID NCT05521698

Recruiting now Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This early-stage trial is testing whether bicalutamide, a drug typically used for prostate cancer, can change a protein linked to bladder cancer growth. Researchers will compare men with non-muscle invasive bladder cancer who take the drug to those who don't. The goal is to see if the drug affects the EGFR protein, which may help guide future treatments. About 80 men will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA RECURRENT NON-MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA

Contacts and locations

Locations

Cedars Sinai Medical Center
NOT_YET_RECRUITING

Los Angeles, California, 90048, United States
National Cancer Institute Urologic Oncology Branch
NOT_YET_RECRUITING

Bethesda, Maryland, 20892, United States
Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITING

Columbus, Ohio, 43210, United States
University of Arizona Cancer Center - Prevention Research Clinic
RECRUITING

Tucson, Arizona, 85719, United States
University of Rochester
NOT_YET_RECRUITING

Rochester, New York, 14642, United States
University of Wisconsin Carbone Cancer Center - University Hospital
RECRUITING

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.